Drugs / Lutetium [177Lu] oxodotreotide/dotatate
Lutetium [177Lu] oxodotreotide/dotatate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04711135 | Aug 2022 → Mar 2024 overdue | digestive system neuroendocrine neoplasm, paraganglioma, pheochromocytoma | Advanced Accelerator Applications | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutetium [177Lu] oxodotreotide/dotatate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04711135 ↗ |
| Known as | 177Lu-DOTATATE | “PURPOSE: NETTER-P, an open-label Phase II study, evaluated the safety and dosimetry of [177Lu]Lu-DOTA-TATE (hereafter 177Lu-DOTATATE) in adolescents with advanced, somatostatin...” PMID 40198358 ↗ Apr 2025 |
| Known as | [177Lu]Lu-DOTA-TATE | “PURPOSE: NETTER-P, an open-label Phase II study, evaluated the safety and dosimetry of [177Lu]Lu-DOTA-TATE (hereafter 177Lu-DOTATATE) in adolescents with advanced, somatostatin...” PMID 40198358 ↗ Apr 2025 |